We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessing Depression in a Geriatric Cancer Population

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00580476
First Posted: December 24, 2007
Last Update Posted: November 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
City of Hope National Medical Center
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
  Purpose
The goal of this study is to learn more about how we measure depression in elderly cancer patients (patients aged 70 and older). Depression is one of the most common causes of emotional distress in the elderly and continues to be under-recognized. This is a problem because depression can have a negative impact on quality of life. The symptoms of depression are linked to poor health outcomes and higher costs of health care. In fact, depression is one of the top five concerns facing the elderly today.

Condition
Breast Cancer Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Assessing Depression in a Geriatric Cancer Population

Resource links provided by NLM:


Further study details as provided by Memorial Sloan Kettering Cancer Center:

Primary Outcome Measures:
  • Test the sensitivity and specificity of the Geriatric Depression Scale-Short Form and two other widely used assessments of depression to detect major and minor depression in a geriatric breast and prostate cancer population. [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • To develop a cut-off score for the GDS that is specific to a cancer population. [ Time Frame: 2 years ]

Enrollment: 201
Study Start Date: September 2006
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
150 patients will be women with breast cancer (75 early stage and 75 late stage)
2
150 will be men with prostate cancer (75 early stage and 75 late stage)

Detailed Description:

We have a few questionnaires that have been used to measure depression, but we do not know how these measures work with people with cancer. This study will help us answer this question. To complete this study, we need people who may or may not be feeling down or depressed.

If you choose to take part, you will be asked to do the following:

  1. Fill out questionnaires that ask about:

    • Your age, eduction, race, and income
    • Your mood

    In all, these questionnaires will take about 10 minutes to complete.

  2. Answer questions about your mood. This will also take about 10 minutes to complete.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   70 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Geriatric Patients with Breast or Prostate Cancer
Criteria

Inclusion Criteria:

  1. Age 70 and older
  2. Diagnosis of early or late stage prostate cancer, or diagnosis of early or late stage breast cancer
  3. Actively engaged in one of the following cancer treatments: chemotherapy, radiation therapy, hormone therapy
  4. Able to provide informed consent
  5. Ability to converse, write and read English

Exclusion Criteria:

1.Major psychopathology or cognitive impairment likely in the judgment of the research staff to interfere with the participation or completion of the protocol.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00580476


Locations
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
City of Hope National Medical Center
Investigators
Principal Investigator: Christian Nelson, Ph.D. Memorial Sloan Kettering Cancer Center
  More Information

Additional Information:
Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00580476     History of Changes
Other Study ID Numbers: 06-100
First Submitted: December 19, 2007
First Posted: December 24, 2007
Last Update Posted: November 8, 2017
Last Verified: November 2017

Keywords provided by Memorial Sloan Kettering Cancer Center:
Breast Cancer
Prostate Cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Depression
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Behavioral Symptoms